HC Wainwright Predicts Increased Earnings for ADMA Biologics

ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) - HC Wainwright lifted their FY2024 earnings per share estimates for shares of ADMA Biologics in a report issued on Friday, November 8th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings per share of $0.55 for the year, up from their previous forecast of $0.49. HC Wainwright has a "Buy" rating and a $26.00 price objective on the stock. The consensus estimate for ADMA Biologics' current full-year earnings is $0.49 per share. HC Wainwright also issued estimates for ADMA Biologics' Q4 2024 earnings at $0.19 EPS, Q1 2025 earnings at $0.20 EPS, Q2 2025 earnings at $0.21 EPS, Q3 2025 earnings at $0.22 EPS and Q4 2025 earnings at $0.24 EPS.

ADMA has been the subject of several other research reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. Raymond James increased their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research report on Friday.

ADMA Biologics Trading Down 0.6 %

NASDAQ ADMA traded down $0.14 on Monday, reaching $22.48. The stock had a trading volume of 4,839,729 shares, compared to its average volume of 3,672,556. The firm has a market capitalization of $5.24 billion, a price-to-earnings ratio of 160.50 and a beta of 0.64. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The stock has a fifty day moving average price of $18.12 and a two-hundred day moving average price of $13.95. ADMA Biologics has a 12-month low of $3.60 and a 12-month high of $23.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to analysts' expectations of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The business's revenue for the quarter was up 78.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.02) EPS.

Institutional Trading of ADMA Biologics

Large investors have recently added to or reduced their stakes in the business. LSV Asset Management acquired a new stake in shares of ADMA Biologics during the 1st quarter worth about $1,028,000. Sei Investments Co. increased its stake in shares of ADMA Biologics by 176.0% in the 1st quarter. Sei Investments Co. now owns 393,481 shares of the biotechnology company's stock valued at $2,597,000 after buying an additional 250,925 shares during the period. Inspire Investing LLC raised its position in shares of ADMA Biologics by 125.2% during the first quarter. Inspire Investing LLC now owns 189,303 shares of the biotechnology company's stock worth $1,249,000 after acquiring an additional 105,256 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of ADMA Biologics by 90.7% during the first quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company's stock valued at $7,717,000 after acquiring an additional 556,175 shares during the period. Finally, ProShare Advisors LLC lifted its stake in shares of ADMA Biologics by 9.2% during the first quarter. ProShare Advisors LLC now owns 54,293 shares of the biotechnology company's stock valued at $358,000 after acquiring an additional 4,570 shares during the period. 75.68% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Young Kwon sold 60,000 shares of the business's stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the sale, the director now owns 241,441 shares in the company, valued at approximately $4,408,712.66. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Young Kwon sold 60,000 shares of the business's stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the sale, the director now owns 241,441 shares of the company's stock, valued at $4,408,712.66. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now owns 153,941 shares in the company, valued at $2,843,290.27. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is currently owned by insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.